Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model

被引:5
|
作者
Opriessnig, Tanja [1 ,2 ,3 ]
Gauger, Phillip C. [3 ]
Gerber, Priscilla F. [1 ,2 ,6 ]
Castro, Alessandra M. M. G. [3 ,7 ]
Shen, Huigang [3 ]
Murphy, Lita [1 ,2 ]
Digard, Paul [1 ,2 ]
Halbur, Patrick G. [3 ]
Xia, Ming [4 ]
Jiang, Xi [4 ,5 ]
Tan, Ming [4 ,5 ]
机构
[1] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland
[2] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland
[3] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA
[4] Cincinnati Childrens Hosp Med Ctr, Div Infect Dis, Cincinnati, OH 45229 USA
[5] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA
[6] Univ New England, Sch Environm & Rural Sci, Anim Sci, Armidale, NSW, Australia
[7] Complexo Educac Fac Metropolitana Unidas, Vet, Real Parque, Sao Paulo, SP, Brazil
来源
PLOS ONE | 2018年 / 13卷 / 01期
基金
英国生物技术与生命科学研究理事会;
关键词
A VIRUS; EXTRACELLULAR DOMAIN; PROTECTIVE EFFICACY; H1N1; INFLUENZA; ANIMAL-MODELS; DUAL VACCINE; SWINE; HEMAGGLUTININ; CANDIDATE; NOROVIRUS;
D O I
10.1371/journal.pone.0191739
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Swine influenza A viruses (IAV-S) found in North American pigs are diverse and the lack of cross-protection among heterologous strains is a concern. The objective of this study was to compare a commercial inactivated A/H1N1/pdm09 (pH1N1) vaccine and two novel subunit vaccines, using IAV M2 ectodomain (M2e) epitopes as antigens, in a growing pig model. Thirty-nine 2-week-old IAV negative pigs were randomly assigned to five groups and rooms. At 3 weeks of age and again at 5 weeks of age, pigs were vaccinated intranasally with an experimental subunit particle vaccine (NvParticle/M2e) or a subunit complex-based vaccine (NvComplex/M2e) or intramuscularly with a commercial inactivated vaccine (Inact/pH1N1). At 7 weeks of age, the pigs were challenged with pH1N1 virus or sham-inoculated. Necropsy was conducted 5 days post pH1N1 challenge (dpc). At the time of challenge one of the Inact/pH1N1 pigs had seroconverted based on IAV nucleoprotein-based ELISA, Inact/pH1N1 pigs had significantly higher pdm09H1N1 hemagglutination inhibition (HI) titers compared to all other groups, and M2e-specific IgG responses were detected in the NvParticle/M2e and the NvComplex/M2e pigs with significantly higher group means in the NvComplex/M2e group compared to SHAMVAC-NEG pigs. After challenge, nasal IAV RNA shedding was significantly reduced in Inact/pH1N1 pigs compared to all other pH1N1 infected groups and this group also had reduced IAV RNA in oral fluids. The macroscopic lung lesions were characterized by mild-to-severe, multifocal-to-diffuse, cranioventral dark purple consolidated areas typical of IAV infection and were similar for NvParticle/M2e, NvComplex/M2e and SHAMVAC-IAV pigs. Lesions were significantly less severe in the SHAMVAC-NEG and the Inact/pH1N1pigs. Under the conditions of this study, a commercial Inact/pH1N1 specific vaccine effectively protected pigs against homologous challenge as evidenced by reduced clinical signs, virus shedding in nasal secretions and oral fluids and reduced macroscopic and microscopic lesions whereas intranasal vaccination with experimental M2e epitope- based subunit vaccines did not. The results further highlight the importance using IAV-S type specific vaccines in pigs.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] Early Outbreak of 2009 Influenza A (H1N1) in Mexico Prior to Identification of pH1N1 Virus
    Hsieh, Ying-Hen
    Ma, Stefan
    Velasco Hernandez, Jorge X.
    Lee, Vernon J.
    Lim, Wei Yen
    [J]. PLOS ONE, 2011, 6 (08):
  • [2] Influenza A(H1N1)pdm09 virus and asthma
    Obuchi, Masatsugu
    Adachi, Yuichi
    Takizawa, Takenori
    Sata, Tetsutaro
    [J]. FRONTIERS IN MICROBIOLOGY, 2013, 4
  • [3] Investigation of Deaths for Severe Acute Respiratory Syndrome by Influenza A(H1N1)pdm09 (pH1N1) in Metropolitan areas of the State of Sao Paulo - Brazil.
    Martins, R. S.
    Junior, S. I.
    Carvalhanas, T. R.
    Ferreira, P. M.
    Spinola, R. I.
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2015, 44 : 134 - 134
  • [4] A(H1N1) pdm09 influenza infection: vaccine inefficiency
    Friedman, Nehemya
    Drori, Yaron
    Pando, Rakefet
    Glatman-Freedman, Aharona
    Sefty, Hanna
    Bassal, Ravit
    Stein, Yaniv
    Shohat, Tamy
    Mendelson, Ella
    Hindiyeh, Musa
    Mandelboim, Michal
    [J]. ONCOTARGET, 2017, 8 (20) : 32856 - 32863
  • [5] Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children
    Kotloff, Karen L.
    Halasa, Natasha B.
    Harrison, Christopher J.
    Englund, Janet A.
    Walter, Emmanuel B.
    King, James C.
    Creech, C. Buddy
    Healy, Sara A.
    Dolor, Rowena J.
    Stephens, Ina
    Edwards, Kathryn M.
    Noah, Diana L.
    Hill, Heather
    Wolff, Mark
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 865 - 871
  • [6] Influenza A(H1N1)pdm09 virus: therapeutics and challenges
    Saxena, Shailendra K.
    Kotikalapudi, Rosaiah
    Tiwari, Sneham
    Muvva, Charuvaka
    [J]. FUTURE VIROLOGY, 2012, 7 (10) : 947 - 950
  • [7] Structural Stability of Influenza A(H1N1)pdm09 Virus
    Yang, Hua
    Chang, Jessie C.
    Guo, Zhu
    Carney, Paul J.
    Shore, David A.
    Donis, Ruben O.
    Cox, Nancy J.
    Villanueva, Julie M.
    Klimov, Alexander I.
    Stevens, James
    [J]. JOURNAL OF VIROLOGY, 2014, 88 (09) : 4828 - 4838
  • [8] Adaptation of influenza A(H1N1)pdm09 virus in experimental mouse models
    Prokopyeva, E. A.
    Sobolev, I. A.
    Prokopyev, M. V.
    Shestopalov, A. M.
    [J]. INFECTION GENETICS AND EVOLUTION, 2016, 39 : 265 - 271
  • [9] Paresthesia Following Pandemic H1N1 (PH1N1) Influenza Vaccine: Reports to the Vaccine Adverse Event Reporting System (VAERS)
    McNeil, Michael M.
    Lewis, Paige
    Cano, Maria V.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 70 - 71
  • [10] Administration of the Adjuvanted pH1N1 Vaccine in Egg-allergic Children at High Risk for Influenza A/H1N1 Disease
    Jane E. SchulerCHEO
    W. James King
    Natalie L. Dayneka
    Lynn Rastelli
    Evelyn Marquis
    Zave Chad
    Charles Hui
    [J]. Canadian Journal of Public Health, 2011, 102 : 196 - 199